Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

Phase 3 Recruiting 294 enrolled Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

Timeline

Start: 2025-02-24
Primary completion: 2027-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Minoxidil	Small molecule	5 %	Topical

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

Summary

Timeline

Drugs

Indications